Ipratropiumbromide Sandoz (Ipratropium Bromide Monohydrate)

Ipratropium bromide is a bronchodilator that acts on the muscarinic receptors of the respiratory tract to improve airflow in obstructive lung diseases.

• Chronic obstructive pulmonary disease (COPD): enhances bronchodilation and reduces symptom severity.
• Asthma: provides add‑on bronchodilation for patients requiring additional control.
• Chronic bronchitis: alleviates bronchospasm and improves ventilation.

• Ipratropium bromide competitively blocks muscarinic acetylcholine receptors (M1, M3) on airway smooth muscle, preventing acetylcholine‑mediated bronchoconstriction. This antagonism leads to relaxation of the bronchial smooth muscle, increased airway diameter, and improved airflow without affecting beta‑adrenergic pathways.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dry mouth: reduced salivary secretion.
• Cough: irritation of the airway.
• Throat irritation: mild soreness after inhalation.
• Headache: transient discomfort.
• Dizziness: occasional light‑headedness.
• Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects

• Paradoxical bronchospasm: worsening of breathing difficulty.
• Angioedema: swelling of face, lips, or tongue.
• Severe allergic reaction: rash, hives, or anaphylaxis.
• Urinary retention: difficulty emptying the bladder.
• Tachycardia: rapid heart rate.
• Increased intraocular pressure: risk for glaucoma patients.

Before prescribing Ipratropium bromide, clinicians should consider several safety aspects.

• Assess respiratory status: evaluate severity of COPD or asthma before initiation.
• Monitor anticholinergic effects: watch for dry mouth, urinary retention, or blurred vision.
• Use caution in narrow‑angle glaucoma: anticholinergic activity may raise intraocular pressure.
• Avoid in patients with known hypersensitivity to ipratropium or atropine derivatives.
• Pregnancy: risk unknown; prescribe only if potential benefit justifies potential risk.
• Store at room temperature: keep in original container, protect from moisture and light.

Ipratropium bromide can interact with other medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Concurrent anticholinergics: may increase anticholinergic burden and side effects.
• Beta‑agonists: combined use can lead to additive cardiovascular effects.
• Potent CYP3A4 inhibitors: may alter metabolism of co‑administered drugs, though effect on ipratropium is minimal.

Moderate Interactions (Monitor Closely)

• Theophylline: monitor serum levels for potential additive bronchodilator effect.
• Diuretics: may exacerbate dry mouth and electrolyte disturbances.
• Antihistamines: increased risk of anticholinergic side effects such as constipation and blurred vision.